173Curated trials
Enterprise Evidence Report · NR-REPORT-V2.0
Poland
Neuroscience Intelligence
Poland neuroscience evidence report: current clinical, research, institution and source-linked intelligence.
Evidence rank #17 of 50 · Data maturity A · Research score 40.5 · Data confidence 100.0 / 100 · Snapshot 2026-10-12 03:34 UTC.
48Recruiting trials
89Publications
52Institutions
Executive interpretation
Poland ranks #17 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.
Methodology status
Methodology NR-REPORT-V2.0. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.
Methodology →Leading sponsors
Merck Sharp & Dohme LLC1810 recruiting
Hoffmann-La Roche156 recruiting
UCB Pharma50 recruiting
Biogen51 recruiting
AbbVie50 recruiting
Jazz Pharmaceuticals50 recruiting
Novo Nordisk A/S41 recruiting
H. Lundbeck A/S41 recruiting
Pfizer40 recruiting
Amgen32 recruiting
Disease activity
Parkinsons32trials
Epilepsy22trials
Alzheimers19trials
Multiple Sclerosis14trials
Other Neurology9trials
Neuromuscular8trials
Depression8trials
Migraine Headache4trials
Autism4trials
Pain Neuropathy4trials
Research institutions
Polish Cardiac SocietyOpenAlexlinked institution
Systems Research InstituteOpenAlexlinked institution
Pomeranian Medical UniversityOpenAlexlinked institution
Maria Curie-Skłodowska UniversityOpenAlexlinked institution
National Institute of Geriatrics, Rheumatology and RehabilitationOpenAlexlinked institution
Children's Memorial Health InstituteOpenAlexlinked institution
Poznań University of TechnologyOpenAlexlinked institution
Medical University of WarsawOpenAlexlinked institution
University of ŁódźOpenAlexlinked institution
Institute of Psychiatry and NeurologyOpenAlexlinked institution
Clinical evidence trail
NCT07798674TreatHSP Platform: Adaptive Natural History Platform for Ataxias, HSPs, and Spastic AtaxiasRECRUITING
NCT07216703A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)RECRUITING
NCT07189715Optimization of Imagery Rescripting Research Using Generative Artificial IntelligenceRECRUITING
NCT07174310A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's DiseaseRECRUITING
NCT07170150A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's DiseaseRECRUITING
NCT07107074Effects of a Widely Used Vaccine Adjuvant in Subjects With Early Alzheimer's Disease Double-blind Study to Assess the Safety and Efficacy of AD04 in Patients With Early Alzheimer's Disease - ADVANCEACTIVE_NOT_RECRUITING
NCT07106632Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic TestsRECRUITING
NCT07018713A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic MigraineRECRUITING
NCT06966700A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)RECRUITING
NCT06961006A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)RECRUITING
NCT06952504A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)RECRUITING
Research evidence trail
PUBMEDHair as a window to mood disorders: Discrimination of bipolar affective disorder using mapping spectroscopy.2027-01-05
PUBMEDLack of beneficial effect of planned treatment interruption in adults with ADHD treated with methylphenidate - clinical evidence.2026-11-01
PUBMEDPeripheral toll-like receptor expression indicates distinct innate immune signatures in schizophrenia spectrum and mood disorders: A systematic review and meta-analysis.2026-11-01
PUBMEDExploring treatment moderators in a randomized clinical trial of virtual reality-based vs. standard cognitive behavioral therapy for paranoia.2026-11-01
PUBMEDReply to "Concerns about 'A Machine Learning Approach to Predicting Clinical Trajectories in Bipolar Disorder'".2026-11-01
PUBMEDEmotional and social loneliness in the longitudinal association between alexithymia and depressive symptoms.2026-10-09
PUBMEDCerebral collision tumor vs. tumor-to-tumor metastasis. Case series with a literature review.2026-10-08
PUBMEDSpinal cord stimulation in the treatment of chronic pain: from evidence to clinical practice - part 1.2026-10-08
PUBMEDDT120 (MM120): a single-dose orally disintegrating formulation of lysergide tartrate for generalized anxiety disorder.2026-10-08
PUBMEDEarly Exposure to a Parent's Alcohol Use Disorder as an Adverse Childhood Experience: Neurobiological and Clinical Consequences in Adulthood.2026-10-06
Sources and provenance
ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.
Limitations
Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.